Top

Graefe's Archive for Clinical and Experimental Ophthalmology

Published in:

01-05-2018 | Letter to the Editor (by invitation)

Detailed analysis of retinal morphology in patients with diabetic macular edema (DME) randomized to ranibizumab or triamcinolone treatment — reply to the letter to the editor

Authors: Sonja Karst, Christoph Mitsch, Christoph Scholda, Ursula Schmidt-Erfurth

Published in: Graefe's Archive for Clinical and Experimental Ophthalmology | Issue 5/2018

Excerpt

We thank Dan and Mihai Călugăru for their letter and interest in our article [1]. In the study we presented, we included patients with visual impairment secondary to center involving diabetic macula edema (DME) (in our paper, we used this term to define central retinal subfield-thickness of more than 300 μm measured with spectral-domain OCT (see Methods section) . We used well-established inclusion criteria that are commonly used in DME trials: central retinal thickness (CRT) > 300 μm in spectral-domain optical coherence tomography (SD-OCT) and best-corrected visual acuity (BCVA) 20/25–20/400 Snellen equivalent. …

Karst SG, Lammer J, Mitsch C et al (2018) Detailed analysis of retinal morphology in patients with diabetic macular edema ( DME ) randomized to ranibizumab or triamcinolone treatment. Graefes Arch Clin Exp Ophthalmol 256(1):49–58CrossRefPubMed

Elman M, Aiello L, Beck R, Bressler N (2010) Randomized trial evaluating ranibizumab plus prompt or deferred laser or triamcinolone plus prompt laser for diabetic macular edema. Ophthalmology 117(6):1064–1077. https://doi.org/10.1016/j.ophtha.2010.02.031.Randomized CrossRefPubMedPubMedCentral

Mitchell P, Bandello F, Schmidt-Erfurth U et al (2011) The RESTORE study: ranibizumab monotherapy or combined with laser versus laser monotherapy for diabetic macular edema. Ophthalmology 118(4):615–625. https://doi.org/10.1016/j.ophtha.2011.01.031 CrossRefPubMed

Bressler SB, Glassman AR, Almukhtar T et al (2016) Five-year outcomes of ranibizumab with prompt or deferred laser versus laser or triamcinolone plus deferred ranibizumab for diabetic macular edema. Am J Ophthalmol 164:57–68. https://doi.org/10.1016/j.ajo.2015.12.025 CrossRefPubMedPubMedCentral

Schmidt-Erfurth U, Lang GE, Holz FG et al (2014) Three-year outcomes of individualized ranibizumab treatment in patients with diabetic macular edema: the RESTORE extension study. Ophthalmology 121(5):1045–1053. https://doi.org/10.1016/j.ophtha.2013.11.041 CrossRefPubMed

Title: Detailed analysis of retinal morphology in patients with diabetic macular edema (DME) randomized to ranibizumab or triamcinolone treatment — reply to the letter to the editor
Authors: Sonja Karst
Christoph Mitsch
Christoph Scholda
Ursula Schmidt-Erfurth
Publication date: 01-05-2018
Publisher: Springer Berlin Heidelberg
Published in: Graefe's Archive for Clinical and Experimental Ophthalmology / Issue 5/2018
Print ISSN: 0721-832X
Electronic ISSN: 1435-702X
DOI: https://doi.org/10.1007/s00417-018-3902-3

Keynote webinar | Spotlight on sleep in brain health

Springer Medicine

Detailed analysis of retinal morphology in patients with diabetic macular edema (DME) randomized to ranibizumab or triamcinolone treatment — reply to the letter to the editor

Excerpt

Keynote webinar | Spotlight on sleep in brain health

Springer Medicine

Excerpt

Please log in to get access to this content

Other articles of this Issue 5/2018

An analysis of ranibizumab treatment and visual outcomes in real-world settings: the UNCOVER study

The effects of aging vitreous on contrast sensitivity function

Pediatric abusive head trauma in Taiwan: clinical characteristics and risk factors associated with mortality

Effects of subtenon-injected autologous platelet-rich plasma on visual functions in eyes with retinitis pigmentosa: preliminary clinical results

Augmented superior rectus transposition procedure in Duane retraction syndrome compared with sixth nerve palsy

Conjunctival melanoma: association of cyclooxygenase-2 tumor expression to prognosis